Join the Takhzyro group to help and get support from people like you.
Takhzyro News
U.S. FDA Approves Takeda’s Takhzyro (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
Takhzyro is the First and Only Prophylaxis Treatment Approved in the U.S. for Children 2 to
Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of Takhzyro (lanadelumab-flyo) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
CAMBRIDGE, Massachusetts, February 9, 2022– Takeda (TSE:4502/NYSE:TAK) today announced the U.S. Food and Drug Administration (FDA) approval of the Takhzyro® (lanadelumab-flyo) injection single-dose pr...
FDA Approves Takhzyro (lanadelumab-flyo) for Hereditary Angioedema
August 23, 2018 – The U.S. Food and Drug Administration today approved Takhzyro (lanadelumab), the first monoclonal antibody approved in the U.S. to treat patients 12 years and older with types I...
Ask a question
To post your own question to this support group, sign in or create an account.